Breaking WORLD PHARMA NEWS

Widely prescribed opioid painkiller tramadol not that effective for easing chronic pain

The strong opioid painkiller, tramadol, is not that effective at easing chronic pain for which it’s widely prescribed, finds a pooled data analysis of the available research, published online in BMJ Evidence Based Medicine.

And it likely increases the risk of serious side effects, including heart disease, the findings indicate, prompting the researchers to conclude that the potential harms of tramadol probably outweigh its benefits, and that its use should be minimised.

Read more …

Microbiome and nanoparticle discoveries hold promise for treating gut pain

Abdominal pain is a hallmark of many digestive disorders, including inflammatory bowel disease and irritable bowel syndrome. In an effort to develop targeted treatments for gut pain, scientists have discovered a new enzyme in gut bacteria and are using nanoparticles to deliver drugs inside cells.

Currently, there are no treatments specifically for gut pain, and existing painkillers are often insufficient at managing symptoms.

Read more …

New antibiotic targets IBD - and AI predicted how it would work before scientists could prove it

Researchers at McMaster University and the Massachusetts Institute of Technology (MIT) have made two scientific breakthroughs at once: they not only discovered a brand-new antibiotic that targets inflammatory bowel diseases (IBD), but also successfully used a new type of AI to predict exactly how the drug works. To their knowledge, this a global first for the AI.

Read more …

Combination of two drugs that fight cardiovascular risk could also help treat the most common liver disease

Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third of the adult population. This disorder is characterized by the accumulation of fat in liver cells, which has severe liver consequences and is also associated with a high mortality rate from cardiovascular disease.​​​​​

Read more …

The 2025 Nobel Prize in Physiology or Medicine

The Nobel Assembly at Karolinska Institutet has decided to award the 2025 Nobel Prize in Physiology or Medicine to:

Mary E. Brunkow
Institute for Systems Biology,
Seattle, USA

Fred Ramsdell
Sonoma Biotherapeutics,
San Francisco, USA

Shimon Sakaguchi
Osaka University,
Osaka, Japan

"for their discoveries concerning peripheral immune tolerance"

Read more …

Immune cell ‘signatures’ could help guide treatment for critically ill patients

When a patient enters the emergency department in critical condition, doctors must quickly run through a crucial list of questions: Does the patient have an infection? If so, is it bacterial or viral? Do they require treatment? Can the patient recover at home safely or do they need to be hospitalized?

Even when an infection is diagnosed, the treatment plan isn’t always clear.

Read more …

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Novartis announced that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Rhapsido is a pill taken twice daily and does not require injections or lab monitoring. It is the first FDA-approved Bruton’s tyrosine kinase inhibitor (BTKi) for CSU.

Read more …

Meet your worm avatar: How microscopic worms are helping find new drugs for rare diseases

The research, led by Dr André Brown and the Behavioural Phenomics group at the LMS, was published last week in BMC Biology. It represents a step toward solving a major challenge in medicine: how to develop treatments for the thousands of rare genetic diseases that currently have none. The work builds on a previous study published earlier this year in eLife, and together they mark a shift in how we can model these diseases and test potential treatments at scale.

Read more …

Experts call for change of heart on hormone replacement therapy after breast cancer

Breast cancer survivors with severe menopausal symptoms should be supported to make an informed decision about whether to have hormone replacement therapy or not, according to an interdisciplinary panel of experts including researchers from UCL.

The study, published in Menopause, provides the most comprehensive review to date on the use of hormone replacement therapy (HRT), also known as menopausal hormone therapy (MHT), in women who have been treated for breast cancer.

Read more …

Researchers show novel immune system boost helps fight cancer cells

In experiments with mouse models of breast, pancreatic, and muscle cancers, researchers at Johns Hopkins All Children’s Hospital report new evidence that a novel means of boosting the natural immune system prevents cancer recurrence and improves survival.

The study, published in Nature Immunology, was federally funded by the National Cancer Institute/NIH.

Read more …